Ads
related to: castrate resistant prostate cancer survival- Learn About Advanced PC
Understand The Symptoms, Diagnosis
And Find Helpful Resources.
- Patient Story Videos
Watch Real Stories Of Patients
Who Have Battled Prostate Cancer.
- Prostate Cancer Symptoms
Find Tips And Resources To Manage
Advanced Prostate Cancer.
- Cancer Progression
Understand The Different Kinds Of
Prostate Cancer & Its Progression.
- Learn About Advanced PC
Search results
Results from the WOW.Com Content Network
Abiraterone acetate was FDA approved in April 2011 for treatment of castration-resistant prostate cancer for patients who have failed docetaxel therapy. Abiraterone acetate inhibits an enzyme known as CYP17, which is used in the body to produce testosterone.
Eventually cancer cells can grow resistant to this treatment. This most-advanced stage of the disease, called castration-resistant prostate cancer, is treated with continued hormone therapy alongside the chemotherapy drug docetaxel. Some tumors metastasize (spread) to other areas of the body, particularly the bones and lymph nodes.
Castration-resistant prostate cancer (CRPC) is prostate cancer that progresses despite extremely low testosterone in the body often due to medical castration. [4] Unlike many other types of prostate cancer, CRPC do not need normal testosterone levels, but they still require regular androgen receptors (AR).
In a phase III trial with 755 men for the treatment of castration-resistant prostate cancer, median survival was 15.1 months for participants receiving cabazitaxel versus 12.7 months for participants receiving mitoxantrone. Cabazitaxel was associated with more grade 3–4 neutropenia (81.7%) than mitoxantrone (58%). [13]
Tasquinimod has been mostly studied in prostate cancer, but its mechanism of action suggests that it could be used to treat other cancers. Castration-resistant prostate cancer (CRPC), formerly called hormone-resistant or hormone-refractory prostate cancer, is prostate cancer that grows despite medical or surgical androgen deprivation therapy.
He published over 250 research papers & book chapters across leading journals. [11] [12] Some of his notable publications are listed below: Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer [13]
Ads
related to: castrate resistant prostate cancer survival